Abstract
The human microbial pathogen Helicobacter pylori colonises the stomach of more than half of the worlds population. The microorganism can induce chronic gastritis, peptic ulceration and more rarely, gastric adenocarcinoma. Highly virulent H. pylori strains carry a cag pathogenicity island (cag PAI), which encodes proteins involved in a specialised type IV secretion system (T4SS). H. pylori induces T4SS-dependent and -independent processes by which H. pylori takes direct command of gastric epithelial cell signaling. The H. pylori effector protein cytotoxin associated gene A (CagA), which is translocated via the T4SS into epithelial cells, contributes to the modulation of cellular functions. In addition, H. pylori transactivates the EGFR, a process involving inter-receptor cross talk and extracellular ADAM metalloproteinase cleavage of membrane bound EGFR ligands. The multiple signal transduction pathways activated during H. pylori infection lead to a complex series of events promoting inappropriate inflammatory responses, epithelial hyperproliferation, epithelial survival and transformation. The H. pylori induced epithelial cellular changes, as well as chemopreventative therapeutic strategies, will be introduced in this review.
Keywords: Helicobacter pylori, CagA, epithelial proliferation, NF-kB, EGFR, ADAM metalloproteinases, c-Met
Current Signal Transduction Therapy
Title: Epithelial Cell Signaling in Helicobacter pylori Infection
Volume: 1 Issue: 1
Author(s): Jean E. Crabtree and Michael Naumann
Affiliation:
Keywords: Helicobacter pylori, CagA, epithelial proliferation, NF-kB, EGFR, ADAM metalloproteinases, c-Met
Abstract: The human microbial pathogen Helicobacter pylori colonises the stomach of more than half of the worlds population. The microorganism can induce chronic gastritis, peptic ulceration and more rarely, gastric adenocarcinoma. Highly virulent H. pylori strains carry a cag pathogenicity island (cag PAI), which encodes proteins involved in a specialised type IV secretion system (T4SS). H. pylori induces T4SS-dependent and -independent processes by which H. pylori takes direct command of gastric epithelial cell signaling. The H. pylori effector protein cytotoxin associated gene A (CagA), which is translocated via the T4SS into epithelial cells, contributes to the modulation of cellular functions. In addition, H. pylori transactivates the EGFR, a process involving inter-receptor cross talk and extracellular ADAM metalloproteinase cleavage of membrane bound EGFR ligands. The multiple signal transduction pathways activated during H. pylori infection lead to a complex series of events promoting inappropriate inflammatory responses, epithelial hyperproliferation, epithelial survival and transformation. The H. pylori induced epithelial cellular changes, as well as chemopreventative therapeutic strategies, will be introduced in this review.
Export Options
About this article
Cite this article as:
Crabtree E. Jean and Naumann Michael, Epithelial Cell Signaling in Helicobacter pylori Infection, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269253
DOI https://dx.doi.org/10.2174/157436206775269253 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Interaction of Small Cationic Peptides with Intact Basement Membranes. A Study Using Intrinsic Optical Signals of Chick Retinas
Current Medicinal Chemistry 99mTc-HYNIC-D4 Peptide: A New Small Radiolabeled Peptide for Non Small Cell Lung Tumor Targeting
Anti-Cancer Agents in Medicinal Chemistry Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Role of Inflammation in the Development of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Clinical Signs, Prevention and Treatment of Viral Infections in Infants
Infectious Disorders - Drug Targets Preoperative Circulating MiR-210, a Risk Factor for Postoperative Delirium Among Elderly Patients with Gastric Cancer Undergoing Curative Resection
Current Pharmaceutical Design Novel 4- Aryl-2(1H)-phthalazinone Derivatives as Cyclooxygenase-2 Inhibitors: Synthesis, Molecular Modeling Study and Evaluation as Promising Anti-inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Critical Functions of lncRNA DGCR5 in Cancers of the Digestive System
Current Pharmaceutical Design Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Epigenetic Regulation of ABCB1 Transporter Expression and Function
Current Pharmacogenomics and Personalized Medicine Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets The Antiproliferative Effect of Soy (<i>Glycine max</i>) Isoflavones Contained in a Nutraceutical on Cancer Cell Lines
Current Nutraceuticals Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles
Current Drug Metabolism Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Current Drug Targets